Network Controllability-Based Prioritization of Candidates for SARS-CoV-2 Drug Repositioning
In a short time, the COVID-19 pandemic has left the world with over 25 million cases and staggering death tolls that are still rising. Treatments for SARS-CoV-2 infection are desperately needed as there are currently no approved drug therapies. With limited knowledge of viral mechanisms, a network c...
Main Authors: | Emily E. Ackerman, Jason E. Shoemaker |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-09-01
|
Series: | Viruses |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4915/12/10/1087 |
Similar Items
-
Evaluation of drug repositioning by molecular docking of pharmaceutical resources available in the Brazilian healthcare system against SARS-CoV-2
by: Matheus V.C. Grahl, et al.
Published: (2021-01-01) -
Identifying Effective Antiviral Drugs Against SARS-CoV-2 by Drug Repositioning Through Virus-Drug Association Prediction
by: Lihong Peng, et al.
Published: (2020-09-01) -
Comparative Review of SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza A Respiratory Viruses
by: Zeinab Abdelrahman, et al.
Published: (2020-09-01) -
The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic
by: Jung-Hyun Won, et al.
Published: (2020-12-01) -
Repurposing Therapeutics for Potential Treatment of SARS-CoV-2: A Review
by: Jennifer Santos, et al.
Published: (2020-06-01)